Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

In the tumor microenvironment, cancer cells activate various signaling pathways to promote their growth. This includes the ...

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...

Alcon AG agreed to acquire Staar Surgical Co. in a $1.5 billion cash transaction that would add Staar’s Evo implantable Collamer lenses (ICL) to treat myopia to the vision giant’s portfolio. Alcon ...

The U.S. Centers for Medicare & Medicaid Services adopted several significant policy changes in the Medicare inpatient final ...

Novartis AG’s financial update included good news about Scemblix (asciminib), a third-generation allosteric tyrosine kinase ...

Casi Pharmaceuticals Inc. announced the U.S. FDA has cleared its IND application for CID-103, a monoclonal antibody targeting ...

The U.S. FDA has approved Innovent Biologics, Inc.’s IND application to initiate a phase I clinical trial of its oral GLP-1R ...

Alterity Therapeutics Ltd. helped develop a new neuroimaging biomarker called the multiple system atrophy index (MSA-AI), ...

Shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) were trading at $393.83, down $78.44, or 16%, on top-line results from the phase II dose-ranging study evaluating the safety and efficacy of its ...

Deep learning tools for protein design can also be used to create molecules that bind to them. Certain peptides, such as ...

After shutting down manufacturers’ efforts last year to offer the mandated 340B discounts on outpatient prescription drugs as a rebate rather than an up-front price, the U.S. Health Resources and ...